

# Contents

<b><i>Subjects</i></b>	<b><i>Page</i></b>
List of abbreviations.....	II
List of Figures.....	V
List of Tables.....	VII
• <b>Introduction</b> .....	1
• <b>Aim of the Work</b> .....	5
• <b>Review of Literature</b>	
♦ <b>Chapter (1): Mineral and Bone Disorders in CKD Patients</b> .....	6
♦ <b>Chapter (2): Calcium Dialysate</b> .....	38
♦ <b>Chapter (3): Management of Mineral and Bone Disorders in CKD Patients</b> .....	53
• <b>Subjects and Methods</b> .....	92
• <b>Results</b> .....	97
• <b>Discussion</b> .....	114
• <b>Summary</b> .....	125
• <b>Conclusion</b> .....	131
• <b>Recommendations</b> .....	132
• <b>References</b> .....	133
• <b>Arabic Summary</b>	

## **List of Abbreviations**

<b>Abb.</b>	<b>Meaning</b>
<b>ABD</b>	: A dynamic bone disease
<b>ALP</b>	: Alkaline phosphatase
<b>AVC</b>	: Aortic valve calcification
<b>BAPTA</b>	: bis(o-aminophenoxy)ethane-N, tetraacetic acid
<b>BP</b>	: Blood Pressure
<b>Ca</b>	: Calcium
<b>Ca MB</b>	: Ca mass balance
<b>Ca x P</b>	: Calcium Phosphorus product
<b>CaR</b>	: Calcium sensing receptor
<b>CI</b>	: Collapse Index
<b>CKD</b>	: Chronic Kidney Disease
<b>CKD-MBD</b>	: Chronic kidney disease –mineral bone disorder
<b>CRP</b>	: C-reactive protein
<b>CV</b>	: Cardiovascular
<b>CVD</b>	: Cardiovascular disease
<b>dCa</b>	: Dialysate calcium
<b>DCOR</b>	: Dialysis Clinical Outcomes Revisited
<b>ECG</b>	: Electrocardiography
<b>ESRD</b>	: End stage renal disease
<b>FDA</b>	: Food and drug association
<b>FGF 23</b>	: Fibroblast growth factor 23
<b>GFR</b>	: Glomerular Filtration Rate
<b>HD</b>	: Hemodialysis

## *List of Abbreviations*

---

<b>HdCa</b>	: High calcium dialysate
<b>HDF</b>	: Haemodiafiltration
<b>HMG-CoA</b>	: Hydroxy-3-methylglutaryl coenzyme
<b>I ca</b>	: Ionized Calcium
<b>IDH</b>	: Intradialytic Hypotension
<b>IDWG</b>	: Interdialytic weight gain
<b>JASN</b>	: Journal of the American society
<b>K</b>	: Potassium
<b>K/DOQI</b>	: Kidney Disease Outcomes Quality Initiative
<b>KDIGO</b>	: Kidney Disease: Improving Global Outcomes
<b>Kg</b>	: Kilogram
<b>LdCa</b>	: Low calcium dialysate
<b>LDL</b>	: Low density lipoproteins
<b>LHD</b>	: Long haemodialysis
<b>LV</b>	: Left ventricle
<b>LVH</b>	: Left ventricular Hypertrophy
<b>MAC</b>	: Mitral annular calcification
<b>Mg</b>	: Magnesium
<b>MGP</b>	: Matrix Gla protein
<b>NDHD</b>	: Nocturnal daily haemodialysis
<b>NSAIDs</b>	: Non steroidal anti inflammatory drugs
<b>Po4</b>	: Phosphours
<b>PTH</b>	: Parathyroid hormone
<b>PVD</b>	: Peripheral vascular disease
<b>QB</b>	: Pump speed
<b>rHuEpo</b>	: Recombinant human erythropoietin

## *List of Abbreviations*

---

<b>SBP</b>	: Systolic blood pressure
<b>SD</b>	: Standard deviation
<b>SDHD</b>	: Short daily haemodialysis
<b>SHD</b>	: Standard haemodialysis
<b>SHPT</b>	: Secondary hyperparathyroidism
<b>SMC</b>	: Smooth muscle cell
<b>SPSS</b>	: Statistical Package for the Social Science
<b>T ca</b>	: Total Calcium
<b>TPN</b>	: Total parenteral nutrition
<b>US</b>	: United States
<b>USRDS</b>	: United States renal data system
<b>VDR</b>	: Vitamin D receptor
<b>VDRA</b> s	: Vitamin D receptor activators
<b>VSMCs</b>	: Vascular smooth muscle cells
<b>1,25(OH)<sub>2</sub>D<sub>3</sub></b>	: 1,25-dihydroxy vitamin D

## List of Figures

<b><u>No.</u></b>	<b><u>Figure</u></b>	<b><u>Page</u></b>
<b><u>1</u></b>	The factors involved in pathogenesis of secondary hyperparathyroidism.	<b>13</b>
<b><u>2</u></b>	Mechanisms by which phosphorus induces PTH secretion.	<b>15</b>
<b><u>3</u></b>	The homeostasis of calcium and phosphorus	<b>17</b>
<b><u>4</u></b>	The factors involved in the pathogenesis of a dynamic bone in CKD adapted from reference with permission.	<b>22</b>
<b><u>5</u></b>	Theories of vascular calcification	<b>27</b>
<b><u>6</u></b>	Possible roles of elevated Calcium and Phosphorus on vascular.	<b>31</b>
<b><u>7</u></b>	Individualization of Dilysate Calcium.	<b>45</b>
<b><u>8</u></b>	Serum calcium during and after dialysis with a high dialysate.	<b>50</b>
<b><u>9</u></b>	Mineral metabolism and bone disease in CKD.	<b>55</b>
<b><u>10</u></b>	A comparison of serum phosphate relative reduction kinetics during three sequential dialysis prescriptions.	<b>69</b>
<b><u>11</u></b>	Approach to Management of bone metabolism and disease in CKD patients on dialysis (stage 5).	<b>73</b>
<b><u>12</u></b>	Change in trabecular bone density: comparison between sevelamer and calcium carbonate treatment.	<b>86</b>
<b><u>13</u></b>	Shows total Ca level on Ca dialysate (1.75mmol/l) and (1.5mmol/l) before and after hemodialysis session. Which is significantly lower on Ca dialysate (1.5mmol/l) than on Ca dialysate (1.75mmol/l) (p value <0.05).	<b>102</b>

<b><u>No.</u></b>	<b><u>Figure</u></b>	<b><u>Page</u></b>
<b><u>14</u></b>	Shows ionized Ca level on Ca dialysate (1.75mmol/l) and (1.5mmol/l) before and after hemodialysis session which is significantly lower on Ca dialysate (1.5mmol/l) than on Ca dialysate (1.75 mmol/l) (p value <0.05).	<b>103</b>
<b><u>15</u></b>	Shows PTH on Ca dialysate (1.75mmol/l) and on Ca dialysate (1.5mmol/l) which is significantly higher on Ca dialysate (1.5mmol/l) than on (1.75mmol/l) (p value <0.05).	<b>104</b>
<b><u>16</u></b>	Shows positive correlation between iPTH and ceatinine on studied patients.	<b>107</b>
<b><u>17</u></b>	Shows positive correlation betweeni PTH and serum phosphorus before hemodialysis session on studed patients.	<b>108</b>
<b><u>18</u></b>	Shows positive correlation between iPTH and calciumx phosphorus product on studied patients.	<b>109</b>
<b><u>19</u></b>	Shows negative correlation between iPTH and serum albumin on studied patients.	<b>110</b>
<b><u>20</u></b>	Shows positive correlation between iPTH and heart rate on studied patients.	<b>111</b>
<b><u>21</u></b>	Shows negative correlation between iPTH and QT interval of studied patients.	<b>112</b>

## **List of Tables**

<b><u>No.</u></b>	<b><u>Table</u></b>	<b><u>Page</u></b>
<b><u>1</u></b>	Usual composition of dialysate.	<b>39</b>
<b><u>2</u></b>	Potential advantages and disadvantages of different dialysate calcium concentrations.	<b>51</b>
<b><u>3</u></b>	Potential advantages and disadvantages of different components of the dialysate.	<b>52</b>
<b><u>4</u></b>	NKF-K/DOQI treatment targets for the management of iPTH, Calcium, Phosphorus and CaxP in patients requiring dialysis.	<b>57</b>
<b><u>5</u></b>	Strategy to control hyperphosphataemia in ESRD.	<b>60</b>
<b><u>6</u></b>	Vitamin D Nomenclature.	<b>71</b>
<b><u>7</u></b>	Causes of a dynamic osteodystrophy.	<b>78</b>
<b><u>8</u></b>	Therapeutic strategies in ABD.	<b>81</b>
<b><u>9</u></b>	Basic patients characteristics and Demographic data.	<b>97</b>
<b><u>10</u></b>	Drug History.	<b>98</b>
<b><u>11</u></b>	Basic Echo.	<b>98</b>
<b><u>12</u></b>	Laboratory results on basic and after shift of Ca dialysate.	<b>99</b>
<b><u>13</u></b>	UF and BP during session.	<b>100</b>
<b><u>14</u></b>	Electrophysiological data.	<b>100</b>
<b><u>15</u></b>	Change of rate rhythm of pulse.	<b>101</b>
<b><u>16</u></b>	Intradialytic Complications.	<b>101</b>

## *List of Tables*

---

<b><u>No.</u></b>	<b><u>Table</u></b>	<b><u>Page</u></b>
<b><u>17</u></b>	Correlations between iPTH, and corresponding degree of change of different parameters before and after hemodialysis session.	<b>105</b>
<b><u>18</u></b>	Correlation between PTH and all parameters on dialysate Ca 1.75mmol/l and 1.5mmol/l.	<b>106</b>
<b><u>19</u></b>	Degree of change correlated to iPTH.	<b>113</b>





---

# Introduction

---





---

# **Aim of the Work**

---





---

# **Review of Literature**

---





---

## *Chapter (1)*

# **Mineral and Bone Disorders in CKD Patients**

---





---

## *Chapter (2)*

# **Calcium Dialysate**

---





---

## *Chapter (3)*

# **Management of Mineral and Bone Disorders in CKD Patients**

---

